TBPH Theravance Biopharma, Inc.Stock Price & Overview
$9.01-0.05 (-0.55%)4:00 PM 09/21/23
NASDAQ | $USD | Post-Market: $9.01 4:27 PM
Charts
FFO (FWD)
PE
Div Rate (TTM)
Yield (TTM)
Short Interest
Market Cap
Volume
Prev. Close
Quant Ranking
Ratings Summary
| Now | 6M ago | |
|---|---|---|
SA Analysts | Not CoveredRating: Not Covered | |
Wall Street | Not CoveredRating: Not Covered | |
Quant | Not CoveredRating: Not Covered | |
Ratings Summary
SA Analysts
Wall Street
Quant
| Now | 3M ago | 6M ago | |
|---|---|---|---|
Valuation | -Rating: Not Covered | ||
Growth | -Rating: Not Covered | ||
Profitability | -Rating: Not Covered | ||
Momentum | -Rating: Not Covered | ||
Revisions | -Rating: Not Covered | ||
See TBPH ratings with Premium.
Company Profile
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company’s product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
Address
- Ugland House
- South Church Street
- PO Box 309
- George Town, KY1-1104
- Cayman Islands
Phone Number
-
Website